海思卡尔 develops vascular and endovascular interventional medical devices, concentrating on implants and tools for special and complex lesions. The company provides technology and device development for implantable interventions. It operates a CDMO platform for the medical device industry to support research translation and manufacturing. 海思卡尔 also undertakes R&D and production services under the medical device registration-holder (MAH) system. Recently the company completed a nearly ¥100M A round financing. The round was led by 乔景资本, with follow-on investments from 宏诚投资, 荣通资本, 奇伦天佑 and 浙江创新发展资本.

Total raised

$14M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2023